カテゴリ： GlobalData, アメリカ, 企業調査

Aimmune Therapeutics Inc (AIMT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aimmune Therapeutics Inc (AIMT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8299
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aimmune Therapeutics Inc (Aimmune) formerly Allergen Research Corp is a clinical-stage biopharmaceutical company that develops proprietary product candidates for the treatment of peanut and other food allergies. The company’s lead product candidate AR101 is used to treat the peanut allergy. Its pipeline program portfolio uses characterized oral desensitization immunotherapy (CODIT), a proprietary approach to oral immunotherapy. Aimmune discovers, develops and commercializes therapies related to food allergy. The company conducts academic research in partnership with various universities and other companies to develop novel product candidates. The company operates in the US and the UK. Aimmune is headquartered in Brisbane, California, the US.

Aimmune Therapeutics Inc (AIMT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Allergen Research Raises USD80 Million in Series B Financing 11
Allergen Research Raises US$17 Million In Series A Financing 13
Partnerships 14
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 14
Aimmune Therapeutics Enters Into Agreement With Nestle Health Science 15
Equity Offering 16
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 16
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 18
Aimmune Therapeutics Raises USD184 Million in IPO 19
Aimmune Therapeutics Inc – Key Competitors 20
Aimmune Therapeutics Inc – Key Employees 21
Aimmune Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Strategy And Business Planning 23
Jun 07, 2017: CoreRx and Aimmune Therapeutics Joint Expansion to Create Pharmaceutical Jobs and Increase the Base of Scientific Capabilities in the Tampa Bay Area 23
Financial Announcements 24
Aug 08, 2018: Aimmune Therapeutics announces second quarter 2018 financial results 24
May 08, 2018: Aimmune Therapeutics Announces First Quarter 2018 Financial Results 25
Mar 12, 2018: Aimmune Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 26
Nov 06, 2017: Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 28
Aug 08, 2017: Aimmune Therapeutics Announces Second Quarter 2017 Financial Results 30
May 08, 2017: Aimmune Therapeutics Announces First Quarter 2017 Financial Results 32
Mar 15, 2017: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 35
Feb 14, 2018: Aimmune Therapeutics Names George du Toit and Wayne Shreffler to Scientific Advisory Board 35
Apr 13, 2017: Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer 36
Product News 37
06/07/2017: Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy 37
Clinical Trials 38
Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO 38
Feb 27, 2018: Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results at the AAAAI-WAO Joint Congress 40
Feb 20, 2018: Aimmune Therapeutics Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy 41
Feb 12, 2018: Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress 44
Jan 10, 2018: Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy 45
Jan 08, 2018: Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy 46
Nov 20, 2017: Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 47
Oct 31, 2017: Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial 48
Oct 19, 2017: Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings 50
Aug 08, 2017: Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy 51
Jul 05, 2017: Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy 52
Jun 20, 2017: Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress 53
Jun 15, 2017: Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 54
Jun 12, 2017: Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy 55
May 11, 2017: Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy 56
Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 57
Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 59
Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Allergen Research Raises USD80 Million in Series B Financing 11
Allergen Research Raises US$17 Million In Series A Financing 13
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 14
Aimmune Therapeutics Enters Into Agreement With Nestle Health Science 15
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 16
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 18
Aimmune Therapeutics Raises USD184 Million in IPO 19
Aimmune Therapeutics Inc, Key Competitors 20
Aimmune Therapeutics Inc, Key Employees 21
Aimmune Therapeutics Inc, Other Locations 22
Aimmune Therapeutics Inc, Subsidiaries 22

List of Figures
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aimmune Therapeutics Inc (AIMT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cardiatis SA：製品パイプライン分析
    Summary Cardiatis SA (Cardiatis) is a medical device company that develops a multilayer technology platform for endovascular aneurysm. The company offers a three dimensional multilayer braided stent system for endovascular aneurysm repair. Its multilayer flow modulator include aortic, peripheral, bi …
  • SciBase AB (SCIB)：医療機器：M&Aディール及び事業提携情報
    Summary SciBase AB (SciBase) is a medical technology company that offers non-invasive detection and monitoring of skin tissue alterations. The company develops point of care device for the accurate detection of malignant melanoma. It offers electrical impedance spectroscopy which uses the varying el …
  • Accelerate Diagnostics Inc (AXDX)：医療機器：M&Aディール及び事業提携情報
    Summary Accelerate Diagnostics Inc (Accelerate) is an in vitro diagnostics company that undertakes the development and commercialization of instrumentation for identification and testing the antibiotic susceptibility of infectious pathogens. Its product portfolio includes Accelerate Pheno system, in …
  • Dynavax Technologies Corp (DVAX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company’s only marketed product Heplisav-B is an adult vaccine for hepatitis B. Its p …
  • Mechanical Technology Inc (MKTY)：企業の財務・戦略的SWOT分析
    Summary Mechanical Technology Inc (MTI) is an electronic equipment company that designs, manufactures, and sells test and measurement instruments and systems. The company offers tools, systems and solutions for markets and applications that require precise measurements and control of products, proce …
  • Consolidated Edison Company of New York, Inc.-エネルギー分野：企業M&A・提携分析
    Summary Consolidated Edison Company of New York, Inc. (CECONY), a subsidiary of Consolidated Edison, Inc. is an energy utility that generates, transmits and distributes electricity; supplies natural gas; and generates and supplies steam. The company provides electricity and related services in New Y …
  • Safran Nacelles Ltd ：企業の戦略・SWOT・財務情報
    Safran Nacelles Ltd - Strategy, SWOT and Corporate Finance Report Summary Safran Nacelles Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Amcor Limited：企業の戦略・SWOT・財務分析
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Saudi Pharmaceutical Industries & Medical Appliances Corp (2070)：製薬・医療：M&Aディール及び事業提携情報
    Summary Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO) develops, manufactures, and sells pharmaceutical products and medical appliances. The company offers its products in anti-infectives, cardio-vascular, diabetes, GIT, iron supplement, men health, musculoskeletal, pschychatric …
  • Sanofi (SAN)：企業の財務・戦略的SWOT分析
    Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Genuine Parts Company：企業の戦略・SWOT・財務分析
    Genuine Parts Company - Strategy, SWOT and Corporate Finance Report Summary Genuine Parts Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • High Arctic Energy Services Inc (HWO)：石油・ガス：M&Aディール及び事業提携情報
    Summary High Arctic Energy Services Inc (High Arctic) is an oil and gas company that provides drilling services and equipment for rentals. The company provides services such as drilling services, matting and equipment rentals, snubbing services and nitrogen services. It offers equipment rentals of l …
  • Southern Company Gas：企業の戦略的SWOT分析
    Southern Company Gas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Oleo e Gas Participacoes SA (OGXP3)：石油・ガス：M&Aディール及び事業提携情報
    Summary Oleo e Gas Participacoes SA (OGX) is an oil and gas company that acquires and explores for oil and natural gas properties. The company operates a diversified portfolio of exploratory blocks located in offshore sedimentary basins in Brazil. It operates blocks located in onshore sedimentary ba …
  • CytoSorbents Corp (CTSO)：企業の財務・戦略的SWOT分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriou …
  • QIAGEN N.V.：企業の戦略・SWOT・財務情報
    QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report Summary QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Odfjell Drilling Ltd (ODL)：企業の財務・戦略的SWOT分析
    Odfjell Drilling Ltd (ODL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Schnell Biopharmaceuticals Inc (003060)-製薬・医療分野：企業M&A・提携分析
    Summary Schnell Biopharmaceuticals Inc (Schnell), formerly Korea Schnell Pharma Co., Ltd. is a healthcare company that offers agents and antibiotics. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusi …
  • Charles River Laboratories International, Inc.：企業のM&A・事業提携・投資動向
    Charles River Laboratories International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Charles River Laboratories International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descriptio …
  • Inretail Peru Corp. (INRETC1)：企業の財務・戦略的SWOT分析
    Inretail Peru Corp. (INRETC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆